Presented by Susan Perlman, MD and Vikram Shakkottai, MD, PhD
Pharmaceutical companies describe the drug development process as a “pipeline.” Now that we have emerging Ataxia medications “in the pipeline” – we need to know that that means. Dr. Perlman and Dr. Shakkottai will take us through the process and help us understand how a rare disease fits into the model systems that pharmaceutical companies use to get a medication to the market.
Learn more: www.ataxia.org
